For investors looking to put $3,000 to work in the share market, ASX 200 growth shares can be a great way to build long-term wealth.
But which shares?
Right now, three ASX 200 growth shares stand out as great long-term buys according to analysts. Here's why they could be worth adding to your portfolio.
Aristocrat Leisure Ltd (ASX: ALL)
The first ASX 200 growth share to look at is Aristocrat Leisure. It is one of the world's largest gaming technology companies, developing and supplying slot machines, digital gaming platforms, and social casino apps.
The company has built a dominant position in the land-based gaming industry while also aggressively expanding into digital gaming through its mobile and online offerings.
One of Aristocrat's biggest strengths is its ability to produce high-margin content that keeps players engaged, which underpins strong recurring revenues.
The company's mobile gaming division, Pixel United, has been another driver of growth in recent years, helping diversify revenue beyond traditional slot machines. In addition, Aristocrat has moved into real-money online gaming, which presents another long-term opportunity.
Combined, Aristocrat looks well-placed to continue growing at a solid rate for years to come.
Bell Potter believes this will be the case. It recently put a buy rating and $85.00 price target on its shares.
Life360 Inc (ASX: 360)
Another ASX 200 growth share to buy and hold could be Life360. It is a fast-growing technology company best known for its family safety and location-sharing app.
This app has approximately 80 million users worldwide and provides real-time tracking, crash detection, emergency assistance, and other safety features that appeal to families, particularly in the US.
Life360 has been rapidly growing its revenue through premium subscriptions and add-on services, including identity protection and roadside assistance. It also recently launched an advertising business to monetise its free users.
Overall, this leaves it well-positioned to continue its strong growth long into the future.
It is for this reason that Goldman Sachs recently put a buy rating and $27.00 price target on its shares.
Pro Medicus Limited (ASX: PME)
Finally, Pro Medicus could be an ASX 200 growth share to buy and hold. It has established itself as one of Australia's most successful healthcare technology companies. The company provides cloud-based medical imaging software to hospitals and radiology groups worldwide.
Pro Medicus' flagship Visage 7 platform allows radiologists to process and analyse medical images faster and more efficiently than traditional systems, helping to improve patient outcomes and reduce costs.
What makes Pro Medicus particularly exciting is its ability to secure long-term, high-margin contracts with some of the biggest healthcare providers in the US. In addition, with a capital-light business model, the company consistently generates strong profit margins and boasts a sizeable cash balance with no debt.
And while its shares certainly aren't cheap, this premium is arguably justified given its strong growth prospects, expanding client base, and dominance in a niche but critical market.
Bell Potter sees a lot of value in its shares at current levels. It recently put a buy rating and $330.00 price target on them.
